Article

Generic version of OAB drug now available

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

Perrigo Co. said it had previously prevailed in litigation related to the drug’s launch at both the district and appellate levels. The product has begun shipping immediately, according to the company.

Trospium, also marketed under the brand name Sanctura XR, is a once-daily medication for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Related Content

PTNS therapy for OAB found durable at 3 years

 

Newer overactive bladder agent viable alternative to antimuscarinics

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Christian Moro, PhD, BSc, BEd, MBus, SFHEA, answers a question during a Zoom video interview
Woman talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Ana Lidia Flores-Mireles, PhD, answers a question during a Zoom video interview
Christian Moro, PhD, BSc, BEd, MBus, SFHEA, answers a question during a Zoom video interview
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Doctor consulting patient | Image Credit: © Pcess609 - stock.adobe.com
Related Content
ELIMINATE trial: uUTI regimen demonstrates initial tolerability, efficacy
November 1st 2024

ELIMINATE trial: uUTI regimen demonstrates initial tolerability, efficacy

Hannah Clarke
A rapid reduction in E coli in the urine was observed among 10 of 16 evaluable patients at 4 hours following the first treatment.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
October 15th 2024

FDA approves IDE for study evaluating underactive bladder device

Benjamin P. Saylor
According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder.”
Destigmatizing Urology: Dr. Winter discusses STDs/STIs
March 22nd 2022

Destigmatizing Urology: Dr. Winter discusses STDs/STIs

Urology Times staff
“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.
FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI
September 9th 2024

FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI

Hannah Clarke
Follow Urology Times' coverage of the full-day FDA advisory committee meeting regarding Iterum Therapeutics' new drug application for oral sulopenem for uncomplicated urinary tract infection.
Female doctor talking with a female patient | Image Credit: © rogerphoto - stock.adobe.com
August 1st 2024

Novel antibiotic discovery tool holds promise to uncover more natural compounds

Philip Abbosh, MD, PhD Kate Gessner, MD, PhD
"Teixobactin, and more broadly, the iChip approach to novel antibiotic discovery, is an exciting development in infection control," write Philip Abbosh, MD, PhD, and Kate Gessner, MD, PhD.
© 2024 MJH Life Sciences

All rights reserved.